—Presentations to be webcast on www.exelixis.com—
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 6, 2018--
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s President and Chief Executive Officer, will provide
an overview of the company at the following investor conferences in
Cowen and Company 38th Annual Health Care Conference:
Exelixis is scheduled to present at 12:00 PM EDT / 9:00 AM PDT on
Monday, March 12, 2018 in Boston.
Barclays Capital Global Healthcare Conference: Exelixis is scheduled
to present at 11:15 AM EDT / 8:15 AM PDT on Tuesday, March 13, 2018 in
Oppenheimer 28th Annual Healthcare Conference: Exelixis is
scheduled to present at 9:45 AM EDT / 6:45 AM PDT on Tuesday, March
20, 2018 in New York.
Needham Healthcare Conference: Exelixis is scheduled to present at
11:00 AM EDT / 8:00 AM PDT on Tuesday, March 27, 2018 in New York.
To access the webcast links, log onto www.exelixis.com
and proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s website at
least 15 minutes prior to each presentation to ensure adequate time for
any software download that may be required to listen to the webcasts.
Replays will also be available at the same location for 14 days.
Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in model
genetic systems, we established a broad drug discovery and development
platform that has served as the foundation for our continued efforts to
bring new cancer therapies to patients in need. We discovered our lead
compounds, cabozantinib and cobimetinib, and advanced them into clinical
development before entering into partnerships with leading
biopharmaceutical companies in our efforts to bring these medicines to
patients globally. We are steadfast in our commitment to prudently
reinvest in our business to maximize the potential of our pipeline. We
intend to supplement our existing therapeutic assets with targeted
business development activities and internal drug discovery – all to
deliver the next generation of Exelixis medicines and help patients
recover stronger and live longer. Exelixis recently earned a spot on
Deloitte’s Technology Fast 500 list, a yearly award program honoring the
500 fastest-growing companies over the past four years. For more
information about Exelixis, please visit www.exelixis.com,
follow @ExelixisInc on Twitter or like Exelixis,
Inc. on Facebook.
Exelixis and the Exelixis logo are registered U.S. trademarks.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180306006635/en/
Source: Exelixis, Inc.
EVP, Public Affairs and
For Exelixis, Inc.